Lv12
30 积分 2021-08-13 加入
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
36分钟前
待确认
Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
22小时前
已完结
Oral PCSK9 Inhibitors as an Emerging Frontier in Lipid Management: A Meta-Analysis
8天前
已完结
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
8天前
已完结
Asian Expert Consensus on Nocturnal Hypertension Management
12天前
已完结
Expert consensus on the treatment of dermatoses with targeted drugs (2025 version)
1个月前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
4个月前
已完结
Innate players in Th2 and non-Th2 asthma - emerging roles for the epithelial cell, mast cell and monocyte/macrophage network
6个月前
已完结
Role of Th1 and Th2 in autoimmunity
6个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
7个月前
已完结
皖公网安备34019202002308
